SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. (FibroGen), announced today that interim results from an ongoing open-label Phase 2 clinical study to evaluate FG-3019 as a treatment for idiopathic pulmonary fibrosis (IPF) continue to suggest that the investigational drug has the potential to stabilize and improve fibrosis in patients with the disease. The results substantiate earlier results reported in an oral presentation at the European Respiratory Society Annual Congress in September 2012.
Help employers find you! Check out all the jobs and post your resume.
